➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
Colorcon
McKinsey
Baxter

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

Litigation Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2018-05-15 216 Opinion - Memorandum Opinion references, U.S. Patent Appl. No. 2006/0240105 (“Devane”) and U.S. Patent No. 8,808,740 (“Huang”). …Pernix’s U.S. Patent No. 9,265,760 (“the ’760 patent”), and claim 1 of Pernix’s U.S. Patent No. 9,339,499…,499 (“the ’499 patent”). Pernix’s patents are directed to methods of treating pain in patients with …patients’ systems. See ’760 patent, col. 2, ll. 41–66. The patented invention encompasses formulations…claims 12, 17, and 19 of the ’760 patent, and claim 1 of the ’499 patent, are likewise directed to methods External link to document
2018-06-08 236 Order reports to challenge Alvogen’s claim that U.S. Patent No. 8,808,740 to Huang is an invalidating prior art reference…party admissions is an issue that is not unique to patent law, Third Circuit law—not Federal Circuit law—…Fed. Cir. 2014) (merits of evidentiary rulings in patent cases reviewed under regional circuit law). As…2016 24 August 2018 1:16-cv-00139 830 Patent None District Court, D. Delaware External link to document
2018-06-08 237 Opinion - Memorandum Opinion groups. Claims 1–4 and 11 of U.S. Patent No. 9,265,760 (“the ’760 patent”) recite a method of treating pain…and 19 of the ’760 patent and claim 1 of U.S. Patent No. 9,339,499 (“the ’499 patent”) recite a method…Importantly, the patent in Mayo “simply describe[d] that relation,” and was thus patent ineligible. Id.…the Court concludes that the asserted claims are patent eligible. Signed by Judge William C. Bryson on …7.1.5, and may be granted only “if the court has ‘patently misunderstood a party, made a decision outside External link to document
2018-08-24 255 Findings of Fact & Conclusions of Law .3d 1338, 1339 (Fed. Cir. 2004); U.S. Pat. No. 8,808,740, col. 19, ll. 3–4; JTX13, at 25. …claimed in the patent, or the use of which is claimed in the patent before the patent’s expiration. … two patents, claims 1–4, 11, 12, 17, and 19 of the ’760 patent, and claim 1 of the ’499 patent. In …the ’760 patent, and claim 1 of the ’499 patent), or both (claims 17 and 19 of the ’760 patent). …Alvogen”) for patent infringement under 35 U.S.C. § 271(e)(2). Pernix is the owner of U.S. Patent Nos. 9,265,760 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKesson
Boehringer Ingelheim
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.